Skip to main content

Mycobacterium peregrinum: bactericidal activity of antibiotics alone and in combination

Abstract

Mycobacterium peregrinum is a rapidly growing mycobacterium that is occasionally associated with disease at different locations. At present, little information is available on antibiotic activity against this microorganism. For this reason, we have carried out a study on the in vitro activity of 15 antibiotics, alone and in combination, against M. peregrinum. Our study shows that the new fluoroquinolones with a C8-methoxy group, especially moxifloxacin, exhibit greater activity against this species. These data should be evaluated in clinical assays or animal models in order to confirm their clinical significance.

This is a preview of subscription content, access via your institution.

References

  1. Brown-Elliot BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716–746.

    Article  Google Scholar 

  2. Marie I, Heliot P, Roussel F, Herve F, Muir JF, Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymiositis treated with infliximab. Rheumatology (Oxford) 2005;44:1201–1202.

    Article  CAS  Google Scholar 

  3. Short WR, Emery C, Bhandary M, O’Donnell JA. Misidentification of Mycobacterium peregrinum, the causal organism of a case of bacteremia and automatic implantable cardioverter defibrillator-associated infection, due to its unusual acid-fast staining characteristics. J Clin Microbiol 2005;43:2015–2017.

    PubMed  Article  Google Scholar 

  4. Rivera-Olivero IA, Guevara A, Escalona A, Oliver M, Perez-Alfonzo R, Piquero J, et al. Soft tissue infections due to non-tuberculous mycobacteria following mesotherapy. What is the price of beauty? Enferm Infecc Microbiol Clin 2006;24:302–306.

    PubMed  Article  Google Scholar 

  5. Cremades R, Santos A, Rodriguez JC, Garcia-Pachon E, Ruiz M, Royo G. In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae. J Chemother 2008;20:43–47.

    PubMed  CAS  Google Scholar 

  6. Fernandez-Roblas R, Esteban J, Cabria F, Lopez JC, Jimenez MS, Soriano F. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 2000;44:181–182.

    PubMed  CAS  Article  Google Scholar 

  7. Guillemin I, Sougakoff W, Cambau E, Revel-Viravau V, Moreau N, Jarlier V. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum. Microbiology 1999;145:2527–2532.

    PubMed  CAS  Google Scholar 

  8. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367–416.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Juan Carlos Rodriguez.

About this article

Cite this article

Santos, A., Cremades, R., Rodriguez, J.C. et al. Mycobacterium peregrinum: bactericidal activity of antibiotics alone and in combination. J Infect Chemother 14, 262–263 (2008). https://doi.org/10.1007/s10156-008-0611-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-008-0611-6

Key words

  • Drug resistance
  • Mycobacterium peregrinum